Janice Clarke, MD
Internal Medicine · Conyers, GANPI 1992368187
Payments from drug & device makers
Across 178 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$425
- Pfizer$329
- Novo Nordisk$298
- GSK$287
- AbbVie$279
- AstraZeneca$253
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,544100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $425 |
| Pfizer | 16 | $329 |
| Novo Nordisk | 16 | $298 |
| GSK | 15 | $287 |
| AbbVie | 12 | $279 |
| AstraZeneca | 15 | $253 |
| Lilly USA, LLC | 12 | $225 |
| Xeris Pharmaceuticals, Inc. | 6 | $138 |
| Boehringer Ingelheim | 7 | $133 |
| Dexcom, Inc. | 6 | $130 |
| Lundbeck LLC | 5 | $107 |
| Bayer | 5 | $106 |
| Exact Sciences | 6 | $105 |
| Phathom Pharmaceuticals, Inc. | 5 | $95 |
| Shield Therapeutics Inc | 4 | $85 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Novartis | 3 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Actelion Pharmaceuticals US, Inc. | 2 | $52 |
| Esperion Therapeutics, Inc. | 2 | $51 |
| Amgen | 3 | $49 |
| Merck | 2 | $34 |
| Corcept Therapeutics | 1 | $24 |
| Dynavax Technologies Corporation | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$3,544 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $165,648 |
| JardianceEmpagliflozin | 94 | $141,021 |
| RybelsusSemaglutide | 48 | $90,691 |
| MounjaroTirzepatide | 57 | $79,833 |
| EliquisApixaban | 71 | $63,982 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $53,716 |
| JanuviaSitagliptin Phosphate | 26 | $34,256 |
| RexultiBrexpiprazole | 20 | $33,802 |
| FarxigaDapagliflozin Propanediol | 32 | $32,551 |
| XareltoRivaroxaban | 23 | $24,764 |
| TradjentaLinagliptin | 22 | $24,472 |
| LinzessLinaclotide | 34 | $21,964 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $17,293 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $3,667 |
| Nifedipine ErNifedipine | 121 | $3,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $298 | $256,339143 claims |
| Boehringer IngelheimJardiance, Tradjenta | $133 | $165,493116 claims |
| Lilly USA, LLCMounjaro | $225 | $79,83357 claims |
| PfizerEliquis | $329 | $63,98271 claims |
| GSKTrelegy Ellipta | $287 | $53,71654 claims |
| MerckJanuvia | $34 | $34,25626 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $425 | $33,80220 claims |
| AstraZenecaFarxiga | $253 | $32,55132 claims |
| AbbVieLinzess | $279 | $21,96434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Conyers
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.